Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Christopher Cunningham

Vascular Surgery Florence, SC Medical Doctor

NPI 1558351122 CMS profile 24619

101 S Ravenel St, Suite 230, Florence, SC 29506

Open in the dashboard

General payments

$13,499

108 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Christopher Cunningham of Florence, SC is reported in the CMS Open Payments database as having received $13,499 across 108 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $346 6
2023 General $2,896 25
2022 General $833 20
2021 General $1,552 18
2020 General $496 5
2019 General $7,377 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Cunningham
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Christopher Cunningham were reported at $0. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Christopher Cunningham Vascular Surgery median Middle half National median
2019 $7,377 $796 $226–$2,363 $163
2020 $496 $348 $118–$1,110 $114
2021 $1,552 $471 $158–$1,421 $132
2022 $833 $725 $222–$2,183 $149
2023 $2,896 $836 $257–$2,440 $160
2024 $346 $909 $252–$2,619 $164
2025 $0 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. LeMaitre Vascular, Inc. $6,502 23 payments
  2. Inari Medical, Inc. $4,196 35 payments
  3. Silk Road Medical, Inc. $687 4 payments
  4. W. L. Gore & Associates, Inc. $678 4 payments
  5. Bard Peripheral Vascular, Inc. $409 5 payments
  6. Medtronic, Inc. $154 2 payments
  7. Cardiovascular Systems Inc. $122 2 payments
  8. Boston Scientific Corporation $113 1 payment
  9. Janssen Pharmaceuticals, Inc $111 8 payments
  10. Philips Electronics North America Corporation $110 1 payment
  11. Other $416 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $5,785 99 payments
  2. Travel and Lodging $4,335 6 payments
  3. Consulting Fee $3,000 2 payments
  4. Education $380 1 payment
Products named General payments · program years 2019–2024
  1. FLOWTRIEVER CATHETER, S $4,342 38 payments
  2. CT THROMBECTOMY SYSTEM KIT $3,340 28 payments
  3. VALVULOTOM $3,096 12 payments
  4. XENOSURE $3,014 3 payments
  5. ENROUTE Transcarotid Stent $489 3 payments
  6. ENHANCE Transcarotid Peripheral Access Kit $489 3 payments
  7. ENROUTE Transcarotid Neuroprotection System $489 3 payments
  8. ENROUTE .014 Guidewire $489 3 payments
  9. EXCLUDER AAA Endoprosthesis $380 1 payment
  10. ClotTriever $355 2 payments
  11. Other $3,729 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

300

Median for Vascular Surgery: 122

Drug cost

$17,973

Median for Vascular Surgery: $14,135

Branded share of claims

95%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 17 $14,064
Clopidogrel Clopidogrel Bisulfate Brand 268 $3,504
Cilostazol Generic 15 $404

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$44,606

Medicare's payments for the services billed

Medicare patients

93

Average age 75

Services billed

151

39 women, 54 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Arthritis 56%
Diabetes 54%
Chronic kidney disease 42%
COPD 41%
Heart failure 28%
Atrial fibrillation 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

108 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record